Press release
Data Demonstrating Sotagliflozin Reduces the Risk of Clinically Important Hypoglycemic Events in Adults with Type 1 Diabetes When Added to Insulin Presented at the 85th Scientific Sessions of the American Diabetes Association (ADA)
Oral presentation highlighted the post-hoc analysis during the “Interventions to Prevent Hypoglycemia: Bench to Bedside” session Treatment with sotagliflozin
About this update from Lexicon Pharmaceuticals, Inc.
[{"type":"text","content":" Oral presentation highlighted the post-hoc analysis during the “Interventions to Prevent Hypoglycemia: Bench to Bedside” session Treatment with sotagliflozin resulted in no increased risk and a reduction in hypoglycemia events, particularly in patients with blood glucose ≤55 mg/dL THE WOODLANDS, Texas, June 23, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced that a post-hoc analysis of clinical study data showing a reduction in hypoglycemic events when sotagliflozin was added to optimized insulin therapy for people with type 1 diabetes (T1D) was presented yesterday during the 85th Scientific Sessions of the American Diabetes Association (ADA) in Chicago, Illinois. The ADA emphasizes that hypoglycemia remains an important patient management issue in T1D. Its Standards of Care in Diabetes -- 2025 clinical update states, \"Health care professionals should be vigilant in preventing hypoglycemia.\" In addition, severe hypoglycemia accounts for 5% of T1D hospitalizations and up to 10% of T1D deaths. Chronic kidney disease (CKD) is an important, independent risk factor for hypoglycemia in people with T1D. Approximately 20% to 40% of people with T1D develop CKD. Treatment with sotagliflozin as an adjunct to insulin therapy has been shown to improve glycemic control while also reducing hypoglycemic events. The aim of this post-hoc analysis was to evaluate the effect of kidney function on hypoglycemia risk in patients with T1D who were being treated with sotagliflozin, a dual inhibitor of SGLT 1 and 2, as an adjunct to optimized insulin therapy. Researchers analyzed pooled data from inTandem 1 and inTandem 2, identically designed 52-week Phase 3 clinical trials in which once-daily 200 mg and 400 mg doses of sotagliflozin were compared to placebo when added to optimized insulin therapy. In these studies, documented hypoglycemia was defined as blood glucose of ≤ 70 mg/dL and ≤ 55 mg/dL, and severe hypoglycemia per the ADA Level 3 definition. Results were evaluated by subgroups defined by estimated glomerular filtration rate (eGFR) cut points: eGFR “This analysis is important because it demonstrated that adding sotagliflozin on top of optimized insulin therapy resulted in fewer people developing significant hypoglycemia,” said Craig Granowitz, M.D., Ph.D., Lexicon’s senior vice president and chief medical off...